Answers are grounded in this paper and cite their sources.
Background/Aims: Biological markers of utility in tracking Alzheimer’s disease (AD) during the presymptomatic prodromal phase are important for prevention studies. Changes in cerebrospinal fluid (CSF) levels of 42-amino-acid β-amyloid (Aβ₄₂), total tau protein (t-tau) and phosphorylated tau at residue 181 (p-tau₁₈₁) during this state are incompletely characterized. Methods: We measured CSF markers in 13 carriers of familial AD (FAD) mutations that are fully penetrant for causing AD (PSEN1 and APP) and in 5 non-mutation-carrying family members. Results: Even among the entirely presymptomatic mutation carriers (n = 9), Aβ₄₂ was diminished (388.7 vs. 618.4 pg/ml, p = 0.004), and t-tau (138.5 vs. 50.5 pg/ml, p = 0.002) and p-tau₁₈₁ (71.7 vs. 24.6 pg/ml, p = 0.003) were elevated. There was a negative correlation between Aβ₄₂ levels and age relative to the family-specific age of dementia diagnosis. Conclusions: Our data are consistent with a decline in CSF Aβ₄₂ levels occurring at least 20 years prior to clinical dementia in FAD.
No takes yet. Share an insight, caveat, or question.
Ringman et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: